Synthesis and Anticonvulsant Activity of Some 2/3-Benzoylaminopropionanilide Derivatives

S. Uysal; U. Calis; Z. Soyer

doi:10.1055/s-0032-1308982

Arzneimittelforschung, Table of Contents

Arzneimittelforschung 2012; 62(06): 295-300
DOI: 10.1055/s-0032-1308982

Original Article

Synthesis and Anticonvulsant Activity of Some 2/3-Benzoylaminopropionanilide Derivatives

S. Uysal

¹Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ege University, Bornova, Izmir, Turkey

,

U. Calis

²Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, Sıhhiye, Ankara, Turkey

,

Z. Soyer

¹Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ege University, Bornova, Izmir, Turkey

› Author Affiliations

Abstract

In this study, the synthesis and anticonvulsant properties of sixteen 2/3-benzoylaminopropionanilide derivatives were described. Molecular design of the compounds has been based on the modification of lacosamide which is a functionalized amino acid with a novel anticonvulsant activity. The structural confirmation of the title compounds was achieved by spectral and analytical data. The anticonvulsant activity profile of synthesized compounds was determined by maximal electroshock (MES) and subcutaneous metrazole (scMet) seizure tests, whereas their neurotoxicity was examined using rotarod test. All these tests were performed in accordance with the procedures of the Antiepileptic Drug Development (ADD) program. The majority of the compounds were effective in the MES or scMet screening tests. None of the compounds showed neurotoxicity according to the rotarod test at studied doses. Most active compounds in the series were 3, 12 and 13, which bearing 2-methyl, 2-ethyl and 2-isopropyl substituent on the N-phenyl ring, respectively.

Key words

propanamide - anilide - lacosamide - α/β-alanine - anticonvulsant activity

Full Text

References

References
1 McNamara OJ. Drugs effective in the therapy of the epilepsies. In: The Pharmacological Basis of Therapeutics. Eds.; Hardman JG, Limbird LE, Gilman Ag. McGraw-Hill; New York: 2001: 521-548
2 McCormick DA, Contreras D. On the cellular and network bases of epileptic seizures. Annu Rev Physiol 2001; 63: 815-846
3 Löscher W, Schmidt D. New horizons in the development of antiepileptic drugs III: Innovative Strategies. Epilepsy Res 2006; 69: 183-272
4 Lin Z, Kabada PK. Molecular targets for the rational design of antiepileptic drugs and related neuroprotective agents. Med Res Rev 1997; 17: 537-572
5 Cramer JA, Mintzer S, Wheless J et al. Adverse effects of antiepileptic drugs: a brief overview of important issues. Expert Rev Neurother 2010; 10 (06) 885-891
6 Meador KJ. Newer anticonvulsants: Dosing strategies and cognition in treating patients with mood disorders and epilepsy. J Clin Psychiatry 2003 64 (supl 8) 30-34
7 Bialer M, Johannessen SI, Kupferberg HJ et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 2004; 1 (1–3) 1-48
8 Bialer M, Johannessen SI, Kupferberg HJ et al. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 2002; 51 (1–2) 31-71
9 Bialer M, Johannessen SI, Kupferberg HJ et al. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res 2001; 43 (01) 11-58
10 Beguin C, Andurkar SV, Jin AY et al. Functionalized amido ketones: new anticonvulsant agents. Bioorg Med Chem 2003; 11: 4275-4285
11 Salome C, Salome-Grosjean E, Stables JP et al. Merging the structural motifs of functionalized amino acids and α-aminoamides: compounds with significant anticonvulsant activities. J Med Chem 2010; 53: 3756-3771
12 Andurkar SV, Stables JP, Kohn H. The anticonvulsant activities of N-benzyl 3-methoxypropionamides. Bioorg Med Chem 1999; 7: 2381-2389
13 Beyreuther BK, Freitag J, Heers C et al. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007; 13 (01) 21-42
14 Kohn H, Sawhney KN, LeGall P et al. Preparation and anticonvulsant activity of a series of functionalized .alpha.-aromatic and .alpha.-heteroaromatic amino acids. J Med Chem 1990; 33: 919-926
15 Kohn H, Sawhney KN, LeGall P et al. Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids. J Med Chem 1991; 34: 2444-2452
16 Kohn H, Sawhney KN, Robertson DW et al. Anticonvulsant properties of N-substituted α,α-diamino acid derivatives. J Pharm Sci 1994; 83 (05) 689-691
17 LeTiran A, Stables JP, Kohn H. Design and evaluation of affinity labels of functionalized amino acid anticonvulsants. J Med Chem 2002; 45: 4762-4773
18 Malawska B. New anticonvulsant agents. Curr Topics Med Chem 2005; 5: 69-85
19 Morieux P, Salome C, Park KD et al. The structure - activity relationship of the 3-oxy site in the anticonvulsant (R)-N-Benzyl 2-Acetamido-3-methoxypropionamide. J Med Chem 2010; 53: 5716-5726
20 Chung SS. New treatment option for partial-onset seizures: efficacy and safety of lacosamide. Ther Adv Neurol Disord 2010; 3 (02) 77-83
21 Klemen A, Halasz P. Lacosamide for the prevention of partial onset seizures in epileptic adults. Neuropsychiatr Dis Treat 2010; 6: 465-471
22 Park KD, Salome C, Cotten SW et al. Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors. J Med Chem 2009; 52: 6897-6911
23 Clark CR, Sansom RT, Lin CM et al. Anticonvulsant activity of some 4-aminobenanilides. J Med Chem 1985; 28: 1259-1262
24 Bailleux V, Valle e L, Nuyts JP et al. Comparative anticonvulsant activity and neurotoxicity of 4–Amino-N-(2,6-dimethylphenyl)phthalimide and prototype antiepileptic drugs in mice and rats. Epilepsia 1995; 36: 559-565
25 Vamecq J, Bac P, Herrenknecht C et al. Synthesis and anticonvulsant and neurotoxic properties of substituted N-Phenyl derivatives of the phthalimide pharmacophore. J Med Chem 2000; 43: 1311-1319
26 Soyer Z, Kılıç FS, Erol K et al. Synthesis and anticonvulsant activity of some ω-(1 H-imidazol-1-yl)-N-phenylacetamide and propionamide derivatives. Il Farmaco 2004; 59: 595-600
27 Soyer Z, Kılıc FS, Erol K et al. The synthesis and anticonvulsant activity of some ω-Phthalimido-N-phenylacetamide and propionamide derivatives. Arch Pharm Pharm Med Chem 2004; 337: 105-111
28 Okubo T. Design, synthesis, and structure–activity relationships of novel tetracyclic compounds as peripheral benzodiazepine receptor ligands. Bioorg Med Chem 2004; 12: 3569-3580
29 Ho B, Crider AM, Stables JP. Synthesis and structure–activity relationships of potential anticonvulsants based on 2-piperidinecarboxylic acid and related pharmacophores. Eur J Med Chem 2001; 36: 265-286
30 Gangi FED. J Am Chem Soc 1955; XLIV: 135-137
31 Schapira CB, Abasolo MI, Perillo IA. 4-Hydroxy-1(2 H)-isoquinolone-3-carboxamides. synthesis and properties. J Heterocyclic Chem 1985; 22: 577-581
32 Byrnes WE. New antiarrhythmic agents. 1. Primary .alpha.-amino anilides. J Med Chem 1979; 22 (10) 1171-1176
33 Pabuccuoglu V, Hesse M. The total synthesis of the pavine alkaloid thalimonine heterocycles. 1997; 45 (09) 1751-1758
34 Fox SW, Winitz M, Pettinga CW. Enzymatic synthesis of peptide bonds. VI. The influence of residue type on papaincatalyzed reactions of some benzoylamino acids with some amino acid anilides. J Am Chem Soc 1953; 75: 5539-5542
35 Barker CC. The dehydration of some β-benzamido-acids with acetic anhydride. J Chem Soc 1954; 317-319
36 Hesse M, Meier H, Zeeh B In: Spectroscopic Methods in Organic Chemistry. Stuttgart, New York: Georg Thieme Verlag; 1997
37 Nakanishi K, Solomon PH In: Infrared Absorption Spectroscopy. 2^nd Ed. San Francisco: Holden-Day Inc.; 1977
38 Kral RL, Penry JP, White BG et al. Antiepileptic drug development: II. anticonvulsant drug screening. Epilepsia 1978; 9: 409-428